Endothelin receptor antagonists influence cardiovascular morphology in uremic rats

Kidney International

Volumn 55, Issue 2, 1999, Pages 512-519

  Nabokov, Alexander V ^a,b   Amann, Kerstin ^a,b   Wessels, Sabine ^a,b   Münter, Klaus ^a,b   Wagner, Jürgen ^a,b   Ritz, Eberhard ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Knoll AG   (Germany)

Author keywords

Blood pressure; Fibrosis; Hypertension; Myocardial arteries; Renal failure; Subtotal nephrectomy; Uremia

Indexed keywords

4 TERT BUTYL N [6 (2 HYDROXYETHOXY) 5 (3 METHOXYPHENOXY) 4 PYRIMIDINYL]BENZENESULFONAMIDE; 5 DIMETHYLAMINO N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; TRANDOLAPRIL;

ANIMAL MODEL; ANIMAL TISSUE; AORTA MEDIA; ARTERIOLE; ARTERY WALL; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; UREMIA;

EID: 0032934833     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.00290.x     Document Type: Article

References (67)

1. 1. Valderrábano F, Berthoux FC, Jones EHP, Mehls O, EDTA-ERA Registry. Report on Management of Renal Failure in Europe, XXV, 1994: End Stage Renal Disease and Dialysis Report. Nephrol Dial Transplant 11(Suppl 1):2-21, 1996
2. 2. EXCERPTS FROM THE USRDS 1996 Annual Data Report. VI. Causes death. Am J Kidney Dis 28(Suppl 2):S93-S102, 1996
3. 3. KAKINUMA Y, KAWAMURA T, BILLS T, YOSHIOKA T, ICHIKAWA I, FOGO A: Blood pressure independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int 42:46-55, 1992
4. 4. AMANN K, NEUSÜB R, RITZ E, IRZYNIEC T, WIEST G, MALL G: Changes of vascular architecture independent of blood pressure in experimental uremia. Am J Hypertens 8:409-417, 1995
5. 5. AMANN K, TÖRNIG J, FLECHTENMACHER CH, NABOKOV A, MALL G, RITZ E: Blood-pressure-independent wall thickening of intramyocardial arterioles in experimental uremia: Evidence for a permissive action of PTH. Nephrol Dial Transplant 10:2043-2048, 1995
6. 6. MALL G, RAMBAUSEK M, NEUMEISTER A, KOLLMER S, VETTERLEIN F, RITZ E: Myocardial interstitial fibrosis in experimental uremia: Implications for cardiac compliance. Kidney Int 33:804-811, 1988
7. 7. MALL G, HUTHER W, SCHNEIDER J, LUNDIN P, RITZ E: Diffuse intermyocardiocytic fibrosis in uremic patients. Nephrol Dial Transplant 5:39-44, 1990
8. 8. ROSTAND SG, BRUNSELL JD, CANNON RO III, VICTOR RG: Cardiovascular complications in renal failure. J Am Soc Nephrol 2:1053-1062, 1991
9. 9. LONDON G, PANNIER B, MARCHAIS S, BENETOS A, SAFAR M: Increased systolic pressure in chronic uremia: Role of arterial wave reflections. Hypertension 20:10-19, 1992
10. 10. AMANN K, RITZ E: Reduced cardiac ischaemia tolerance in uremia: What is the role of structural abnormalities of the heart? Nephrol Dial Transplant 11:1238-1241, 1996
11. 11. TÖRNIG J, AMANN K, RITZ E, NICHOLS C, ZEIER M, MALL G: Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure: The effects of ramipril, nifedipine and moxonidine. J Am Soc Nephrol 7:667-675, 1996
12. 12. ORISIO S, BENIGNI A, BRUZZI I, CORNA D, PERICO N, ZOJA C, BENATTI L, REMUZZI G: Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int 43:354-358, 1993
13. 13. BENIGNI A, ZOJA C, CORNA D, ORISIO S, LONGARETTI L, BERTANI T, REMUZZI G: A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 44:440-444, 1993
14. 14. NABOKOV A, AMANN K, WAGNER J, MÜNTER K, RITZ E: Influence of specific and non-specific endothelin receptor antagonists on renal morphology in rats with surgical renal ablation. Nephrol Dial Transplant 11:514-520, 1996
15. 15. BENIGNI A, ZOJA C, CORNA D, ORISIO S, FACCHINETTI D, BENATTI L, REMUZZI G: Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney. Am J Kidney Dis 27:416-423, 1996
16. 16. KOHNO M, MURAKAWA K, HORIO T, YOKOKAWA K, YASUNARI K, FUKUI T, TAKEDA T: Plasma immunoreactive endothelin 1 in experimental malignant hypertension. Hypertension 18:93-100, 1991
17. 17. YASUDA M, KOHNO M, TAHARA A, ITAGANE H, TODA I, AKIOKA K, TERAGAKI M, OKU H, TAKEUCHI K, TAKEDA T: Circulating immunoreactive endothelin in ischemic heart disease. Am Heart J 119:801-806, 1990
18. 18. LERMAN A, KUBO SH, TSCHUMPERLIN LK, BURNETT JC JR: Plasma endothelin concentrations in humans with end stage heart failure and after heart transplantation. J Am Coll Cardiol 20:849-853, 1992
19. 19. SUZUKI T, KUMAZAKI T, MITSUI Y: Endothelin-1 is produced and secreted by neonatal rat cardiac myocytes in vitro. Biochem Biophys Res Commun 191:823-830, 1993
20. 20. ITO H, HIRATA Y, ADACHI S, TANAKA M, TSUJINO M, KOIKE A, NOGAMI A, MARUMO F, HIROE M: Endothelin-1 is an autocrine/ paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest 92:398-403, 1993
21. 21. LARIVIÈRE R, DENG LY, DAY R, SVENTEK P, THIBAULT G, SCHIFFRIN EL: Increased endothelin-1 gene expression in the endothelium of coronary arteries and in the endocardium of DOCA-salt hypertensive rats. J Mol Cell Cardiol 27:2123-2131, 1995
22. 22. YANAGISAWA M, KURIHARA H, KIMURA S, TOMOBE Y, KOBAYASHI M, MITSUI Y, YAZAKI Y, GOTO K, MASAKI T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411-415, 1988
23. 23. HAHN AWA, RESINK TJ, SCOTT-BURDEN T, POWELL J, DOHI Y, BUHLER FR: Stimulation of endothelin mRNA and secretion in rat vascular smooth muscle cells: A novel autocrine function. Cell Regul 1:649-659, 1990
24. 24. MOLENAAR P, O'REILLY G, SHARKEY A, KUC RE, HARDING DP, PLUMPTON C, GRESHAM GA, DAVENPORT AP: Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res 72:526-538, 1993
25. 25. DENG LY, LI J-S, SCHIFFRIN EL: Endothelin receptor subtypes in resistance arteries from humans and from rats. Cardiovasc Res 29:532-535, 1995
26. 26. HORI S, KOMATSU Y, SHIGEMOTO R, MIZUNO N, NAKANISHI S: Distinct tissue distribution and cellular localization of two messenger ribonucleic acids encoding different subtypes of rat endothelin receptors. Endocrinology 130:1885-1895, 1992
27. B sites in human coronary vasculature. J Cardiovasc Pharmacol 26(Suppl 3):S351-S354, 1995
28. 28. YOKOKAWA K, TAHARA H, KOHNO M, MURAKAWA K, YASUNARI K, NAKAGAWA K, HAMADA T, OTANI S, YANAGISAWA M, TAKEDA T: Hypertension associated with endothelin secreting malignant hemangioendothelioma. Ann Intern Med 114:213-215, 1991
29. 29. WATANABE T, SUZUKI N, SHIMAMOTO N, FUJINO M, IMADA A: Contribution of endogenous endothelin in the extension of myocardial infarct size in rats. Circ Res 69:370-377, 1991
30. 30. CAVERO PG, MILLER WL, HEUBLEIN DM, MARGULIES KB, BURNETT JC JR: Endothelin in experimental congestive heart failure in the anesthetized dog. Am J Physiol 259:F312-F317, 1990
31. 31. AMANN K, RITZ E, WIEST G, KLAUS G, MALL G: A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 4:1814-1819, 1994
32. 32. MATTFELDT T, MALL G, GHAREHBAGHI H, MÖLLER P: Estimation of surface area and length with the orientator. J Microsc 159:301-317, 1990
33. 33. AMANN K, KRONENBERG G, GEHLEN F, ORTH SR, MÜNTER K, EHMKE H, MALL G, RITZ E: Cardiac remodeling in experimental renal failure: An immunohistochemical study. Nephrol Dial Transplant 73:1958-1967, 1998
34. 34. GUARDA E, KATWA LC, MYERS PR, TYAGI SC, WEBER KT: Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res 27:2130-2134, 1993
35. 35. KATWA LC, GUARDA E, WEBER KT: Endothelin receptors in cultured adult rat cardiac fibroblasts. Cardiovasc Res 27:2125-2129, 1993
36. 36. ENOKI T, MIWA S, SAKAMOTO A, MINOWA T, KOMURO T, KOBAYASHI S, NINOMIYA H, MASAKI T: Long-lasting activation of cation current by low concentration of endothelin-1 in mouse fibroblasts and smooth muscle cells of rabbit aorta. Br J Pharmacol 115:479-485, 1995
37. 37. Deleted in proof
38. 38. AMANN K, WOLF B, NICHOLS C, TÖRNIG J, SCHWARZ U, ZEIER M, MALL G, RITZ E: Aortic changes in experimental renal failure: Hyperplasia of hypertrophy of smooth muscle cells? Hypertension 29:770-775, 1997
39. 39. DAY R, LARIVIÈRE R, SCHIFFRIN EL: In situ hybridization shows increased endothelin-1 mRNA levels in endothelial cells of blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Am J Hypertens 8:294-300, 1995
40. 40. SCHIFFRIN EL, LARIVIÈRE R, LI J-S, SVENTEK P, TOUYZ RM: Deoxycorticosterone acetate plus salt induce overexpression of vascular endothelin-1 and severe vascular hypertrophy in spontaneously hypertensive rats. Hypertension 25:769-773, 1995
41. 41. SVENTEK P, LI J-S, GROVE K, DESCHEPPER CF, SCHIFFRIN EL: Vascular structure and expression of endothelin-1 gene in L-NAME-treated spontaneously hypertensive rats. Hypertension 27:49-55, 1996
42. 42. LERMAN A, EDWARDS BS, HALLETT JW, HEUBLEIN DM, SANDBERG SM, BURNETT JC JR: Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 325:997-1001, 1991
43. 43. HIRATA Y, TAKAGI Y, FUKUDA Y, MARUMO F: Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis 78:225-228, 1989
44. 44. BOBIK A, GROOMS A, MILLAR JA, MITCHELL A, GRINPUKEL S: Growth factor activity of endothelin on vascular smooth muscle. Am J Physiol 258:C408-C415, 1990
45. 45. LI J-S, LARIVIÈRE R, SCHIFFRIN EL: Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats: Evidence for a role of endothelin in vascular hypertrophy. Hypertension 24:183-188, 1994
46. 46. SCHIFFRIN EL, LARIVIÈRE R, LI J-S, SVENTEK P, TOUYZ RM: Enhanced expression of endothelin-1 gene may cause blood pressure-independent vascular hypertrophy. J Cardiovasc Pharmacol 26 (Suppl 3):S5-S8, 1995
47. 47. GRIFFIN KA, PICKEN M, BIDANI AK: Radiotelemetric BP monitoring, antihypertensives and glomeruloprotection in remnant kidney model. Kidney Int 46:1010-1018, 1994
48. 48. OHLSTEIN EH, DOUGLAS SA: Endothelin-1 modulates vascular smooth muscle structure and vasomotion: Implications in cardiovascular pathology. Drug Dev Res 29:108-128, 1993
49. 49. CHUA BHL, CHUA CC, DIGLIO CA, SIU BB: Regulation of endothelin-1 mRNA by angiotensin II in rat heart endothelial cells. Biochem Biophys Acta 1178:201-206, 1993
50. 50. IMAI T, HIRATA Y, EMORI T, YANAGISAWA M, MASAKI T, MARUMO F: Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension 19:753-757, 1992
51. 51. SUNG CP, ARLETH AJ, STORER BL, OHLSTEIN EH: Angiotensin type I receptors mediate smooth muscle proliferation and endothelin biosynthesis in rat vascular smooth muscle. J Pharmacol Exp Ther 271:429-437, 1994
52. 52. KANNO K, HIRATA Y, TSUJINO M, IMAI T, SHICHIRI M, ITO H, MARUMO F: Up-regulation of ETb receptor subtype mRNA by angiotensin II in rat cardiomyocytes. Biochem Biophys Res Commun 194:1282-1287, 1993
53. 53. KAWAGUCHI H, SAWA H, YASUDA H: Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary artery endothelial cells. J Mol Cell Cardiol 22:839-842, 1990
54. 54. CHANG DP, CLAVELL A, KEISER J, BURNETT JC JR: Effects of reninangiotensin system in mediating endothelin-induced renal vasoconstriction: Therapeutic implications. J Hypertens 12(Suppl 4):S43-S49, 1994
55. 55. MORTENSEN LH, FINK GD: Captopril prevents chronic hypertension produced by infusion of endothelin-1 in rats. Hypertension 19:676-680, 1992
56. 56. KAASJAGER KAH, KOOMANS HA, RABELINK TJ: Effectiveness of enalapril versus nifedipine to antagonize blood pressure and the renal response to endothelin in humans. Hypertension 25:620-625, 1995
57. 57. NEYSES L, NOUSKAS J, OBERDORF S, VETTER H: Action of an ACE inhibitor on myocardial early growth response. J Cardiovasc Pharmacol 20(Suppl B):S12-S14, 1992
58. 58. YOSHIDA H, NAKAMURA M: Inhibition by angiotensin converting enzyme inhibitors of endothelin secretion from cultured human endothelial cells. Life Sci 50:195-200, 1992
59. 59. UEMASU J, MUNEMURA C, FUJIHARA M, KAWASAKI H: Inhibition of plasma endothelin-1 concentration by captopril in patients with essential hypertension. Clin Nephrol 41:150-152, 1994
60. 60. LARIVIÈRE R, LEBEL M, KINGMA I, GROSE J-H, BOUCHER D: Effect of losartan on vascular and renal endothelin-1 production in rats with reduced renal mass. (abstract) J Am Soc Nephrol 7:1567, 1996
61. 61. WEBB ML, DICKINSON KE, DELANEY CL, LIU ECK, SERAFINO R, COHEN RB, MONSHIZADEGAN H, MORELAND S: The endothelin receptor antagonist, BQ-123, inhibits angiotensin II-induced contraction in rabbit aorta. Biochem Biophys Res Commun 185:887-892, 1992
62. 62. TEERLINK JR, LÖFFLER B-M, HESS P, MAIRE J-P, CLOZEL M, CLOZEL J-P: Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure: Acute effects of the endothelin receptor antagonist Ro 47-0203 (Bosentan). Circulation 90:2510-2518, 1994
63. 63. BENIGNI A, MAFFI R, CORNA D, BENEDETTI G, BRUZZI I, ZOJA C, REMUZZI G: Beneficial effect of contemporary blocking of angiotensin II (AII) and endothelin-1 (ET-1) in experimental membranous nephropathy. (abstract) J Am Soc Nephrol 8:611A, 1997
64. 64. NABOKOV A, AMANN K, GASSMANN P, SCHWARZ U, ORTH S, RITZ E: The renoprotective effect of angiotensin-converting enzyme inhibitors in experimental chronic renal failure is not dependent on enhanced kinin activity. Nephrol Dial Transplant 13:173-176, 1997
65. B endothelin receptor antagonist bosentan. Can J Physiol Pharmacol 73:390-398, 1995
66. 66. KARAM H, HEUDES D, GONZALES M-F, LÖFFLER B-M, CLOZEL M, CLOZEL J-P: Respective role of humoral factors and blood pressure in aortic remodeling of DOCA hypertensive rats. Am J Hypertens 9:991-998, 1996
67. 67. NGUYEN PV, PARENT A, DENG LY, FLUCKIGER JP, THIBAULT G, SCHIFFRIN EL: Endothelin vascular receptors and responses in deoxycorticosterone acetate-salt hypertensive rats. Hypertension 19(Suppl II):II98-II104, 1992